(Q43184160)

15 November 2017

0 references

Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution? (English)

1 reference

15 November 2017

0 references

Stephen A Harrison

1

1 reference

PubMed ID

20101743

15 November 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

15 November 2017

1 reference

15 November 2017

51

1 reference

15 November 2017

2

1 reference

15 November 2017

366-369

1 reference

Non-alcoholic fatty liver disease: is bariatric surgery the answer?

15 November 2017

1 reference

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

21 January 2018

1 reference

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

21 January 2018

1 reference

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

Adipokines in liver diseases

21 January 2018

1 reference

High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase

21 January 2018

1 reference

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes

21 January 2018

1 reference

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

21 January 2018

1 reference

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study

21 January 2018

1 reference

Association between nonalcoholic fatty liver disease and coronary artery disease

21 January 2018

1 reference

Long-term follow-up of patients with nonalcoholic fatty liver

21 January 2018

1 reference

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.23473

1 reference

release_4r7ja7a7nvbc5ofuciwpzmiya4

15 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4r7ja7a7nvbc5ofuciwpzmiya4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

20101743

1 reference

PubMed ID

20101743